Ichiro Nakano

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. doi Extracellular vesicles in the biology of brain tumour stem cells--Implications for inter-cellular communication, therapy and biomarker development
    Ichiro Nakano
    Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States Electronic address
    Semin Cell Dev Biol 40:17-26. 2015
  2. doi Therapeutic potential of targeting glucose metabolism in glioma stem cells
    Ichiro Nakano
    Associate Professor, Director of Neural Cancer Stem Cell Program, The Ohio State University, James Comprehensive Cancer Center, Department of Neurological Surgery, 385 Wiseman Hall, 400 W 12th St, Columbus, OH 43210, USA 1 614 292 0358 1 614 688 4882
    Expert Opin Ther Targets 18:1233-6. 2014
  3. pmc Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway
    Ichiro Nakano
    Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Neuro Oncol 13:622-34. 2011
  4. pmc Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner
    Chunyu Gu
    Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, USA
    Stem Cells 31:870-81. 2013
  5. pmc MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells
    Kaushal Joshi
    Department of Neurological Surgery, The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    Stem Cells 31:1051-63. 2013
  6. pmc Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells
    Tae Hyong Kim
    Dardinger Neuro oncology Center, Department of Neurological Surgery, Ohio State University, Columbus, Ohio T H K, J S, S H K, A K P, I N, B K, C H K Solid Tumor Program at the James Comprehensive Cancer Center, Columbus, Ohio T H K, J S, A K P, C H K Center for Biostatistics, Ohio State University, Columbus, Ohio X M Department of Radiation Oncology, Ohio State University, Columbus, Ohio K P Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio J Y Department of Molecular and Cellular Biochemistry, Ohio State University Wexner Medical Center, Columbus, Ohio S O Y
    Neuro Oncol 16:1354-64. 2014
  7. pmc Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb
    Takeshi Miyazaki
    Department of Neurological Surgery, Dardinger, Center for Neuro Oncology, James Cancer Hospital and The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 18:1268-80. 2012
  8. pmc Laminin alpha 2 enables glioblastoma stem cell growth
    Justin D Lathia
    Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
    Ann Neurol 72:766-78. 2012
  9. pmc Multi-kinase inhibitor C1 triggers mitotic catastrophe of glioma stem cells mainly through MELK kinase inhibition
    Mutsuko Minata
    Department of Neurological Surgery, The Ohio State University Medical Center, Columbus, Ohio, United States of America
    PLoS ONE 9:e92546. 2014
  10. pmc EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner
    Sung Hak Kim
    Department of Neurological Surgery, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Stem Cell Reports 4:226-38. 2015

Collaborators

Detail Information

Publications26

  1. doi Extracellular vesicles in the biology of brain tumour stem cells--Implications for inter-cellular communication, therapy and biomarker development
    Ichiro Nakano
    Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States Electronic address
    Semin Cell Dev Biol 40:17-26. 2015
    ..The GBM/GSC subtype-specific differentials in EV cargo of proteins, transcripts, microRNA and DNA may enable detection of the dynamics of the stem cell compartment and result in biological effects that remain to be fully characterized. ..
  2. doi Therapeutic potential of targeting glucose metabolism in glioma stem cells
    Ichiro Nakano
    Associate Professor, Director of Neural Cancer Stem Cell Program, The Ohio State University, James Comprehensive Cancer Center, Department of Neurological Surgery, 385 Wiseman Hall, 400 W 12th St, Columbus, OH 43210, USA 1 614 292 0358 1 614 688 4882
    Expert Opin Ther Targets 18:1233-6. 2014
    ..Such concept may better elucidate the mechanisms of how tumors gain cellular and molecular complexity and guide us develop novel and effective targeted therapies. ..
  3. pmc Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway
    Ichiro Nakano
    Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Neuro Oncol 13:622-34. 2011
    ..Together, this study may be the first model to partially target stemlike GBM cells through a MELK-mediated pathway with siomycin A to pave the way for effective treatment of GBM...
  4. pmc Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner
    Chunyu Gu
    Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, USA
    Stem Cells 31:870-81. 2013
    ..Together, our data indicate that GSCs, but not normal cells, depend on JNK-driven MELK/c-JUN signaling to regulate their survival, maintain GSCs in an immature state, and facilitate tumor radioresistance in a p53-dependent manner...
  5. pmc MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells
    Kaushal Joshi
    Department of Neurological Surgery, The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    Stem Cells 31:1051-63. 2013
    ..Collectively, our data indicate that FOXM1 signaling through its direct interaction with MELK regulates key mitotic genes in GSCs in a PLK1-dependent manner and thus, this protein complex is a potential therapeutic target for GBM...
  6. pmc Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells
    Tae Hyong Kim
    Dardinger Neuro oncology Center, Department of Neurological Surgery, Ohio State University, Columbus, Ohio T H K, J S, S H K, A K P, I N, B K, C H K Solid Tumor Program at the James Comprehensive Cancer Center, Columbus, Ohio T H K, J S, A K P, C H K Center for Biostatistics, Ohio State University, Columbus, Ohio X M Department of Radiation Oncology, Ohio State University, Columbus, Ohio K P Division of Hematology, Department of Internal Medicine, Ohio State University, Columbus, Ohio J Y Department of Molecular and Cellular Biochemistry, Ohio State University Wexner Medical Center, Columbus, Ohio S O Y
    Neuro Oncol 16:1354-64. 2014
    ..Although these findings suggest that piperlongumine could be useful for treating cancers, the mechanism by which the drug selectively kills cancer cells remains unknown...
  7. pmc Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb
    Takeshi Miyazaki
    Department of Neurological Surgery, Dardinger, Center for Neuro Oncology, James Cancer Hospital and The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 18:1268-80. 2012
    ..Glioma stem cells (GSC) are a critical therapeutic target of glioblastoma multiforme (GBM)...
  8. pmc Laminin alpha 2 enables glioblastoma stem cell growth
    Justin D Lathia
    Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
    Ann Neurol 72:766-78. 2012
    ..Extracellular matrix (ECM) cues instruct neural stem/progenitor cell-niche interactions, and the objective of our study was to elucidate its composition and contribution to GSC maintenance in the perivascular niche...
  9. pmc Multi-kinase inhibitor C1 triggers mitotic catastrophe of glioma stem cells mainly through MELK kinase inhibition
    Mutsuko Minata
    Department of Neurological Surgery, The Ohio State University Medical Center, Columbus, Ohio, United States of America
    PLoS ONE 9:e92546. 2014
    ..Lastly, C1 treatment sensitizes GSCs to radiation treatment. Collectively, these data indicate that targeting MELK kinase activity is a promising approach to attenuate GBM growth by eliminating GSCs in tumors. ..
  10. pmc EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner
    Sung Hak Kim
    Department of Neurological Surgery, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Stem Cell Reports 4:226-38. 2015
    ....
  11. pmc Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1
    Agnieszka Bronisz
    Authors Affiliations Harvey Cushing Neuro oncology Laboratories, Department of Neurosurgery, Brigham and Women s Hospital, Harvard Medical School, Boston Neuroscience Center at Massachusetts General Hospital, Charlestown, Massachusetts Departments of Neurological Surgery and Molecular and Cellular Biochemistry, The Ohio State University Medical Center, Columbus, Ohio
    Cancer Res 74:738-50. 2014
    ....
  12. pmc Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex
    Hacer Güvenç
    Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA
    Clin Cancer Res 19:631-42. 2013
    ..Glioblastoma multiforme (GBM) is a devastating disease. Recent studies suggest that the stem cell properties of GBM contribute to the development of therapy resistance...
  13. pmc Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake
    William A Flavahan
    1 Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, Ohio, USA 2 Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Nat Neurosci 16:1373-82. 2013
    ..As altered metabolism represents a cancer hallmark, metabolic reprogramming may maintain the tumor hierarchy and portend poor prognosis. ..
  14. pmc Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3
    Ping Mao
    Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 110:8644-9. 2013
    ..Inhibition of ALDH1A3-mediated pathways therefore might provide a promising therapeutic approach for a subset of HGGs with the Mes signature...
  15. ncbi RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model
    Tae Jin Lee
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Oncotarget 6:14766-76. 2015
    ..This study provides possible application of pRNA-3WJ RNP for specific delivery of therapeutics such as siRNA, microRNA and/or chemotherapeutic drugs into glioblastoma cells without inflicting collateral damage to healthy tissues. ..
  16. doi Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells
    Peng Cheng
    Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA Department of Neurosurgery, The First Hospital, China Medical University, Shenyang, Liaoning 110001, China
    Stem Cell Reports 4:899-913. 2015
    ..In conclusion, we identified AXL as a potential molecular target for novel approaches to treat glioblastoma and other solid cancers...
  17. doi Therapeutic targeting of VEGF in the treatment of glioblastoma
    Lizbeth Robles Irizarry
    Neurological Institute, Cleveland Clinic, The Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center, Cleveland, OH, USA
    Expert Opin Ther Targets 16:973-84. 2012
    ..Targeting angiogenesis is hypothesized to arrest tumor growth and hence VEGF is an attractive therapeutic target...
  18. pmc Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype in glioma and other cancers
    Ranjit Ganguly
    Authors Affiliations Department of Neurological Surgery The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio Departments of Psychiatry, Pharmacology, and Pediatrics and The Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California
    Mol Cancer Ther 13:1393-8. 2014
    ..This review summarizes the current molecular understanding of MELK and the recent preclinical studies about MELK as a cancer therapeutic target...
  19. pmc CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway
    Mayumi Jijiwa
    Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 6:e24217. 2011
    ..Collectively, these data indicate that a subset of GBM expresses high CD44 in BTSC, and its growth may depend on CD44v6/AKT pathway...
  20. doi Detoxification of oxidative stress in glioma stem cells: mechanism, clinical relevance, and therapeutic development
    Sung Hak Kim
    Dardinger Neuro oncology Center, Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio
    J Neurosci Res 92:1419-24. 2014
    ..In addition, the therapeutic potential of some of the recently identified antioxidant chemotherapeutic agents and avenues for future research in this area are discussed...
  21. pmc Suppression of peroxiredoxin 4 in glioblastoma cells increases apoptosis and reduces tumor growth
    Tae Hyong Kim
    Dardinger Center for Neuro oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA
    PLoS ONE 7:e42818. 2012
    ..In a syngenic orthotopic transplantation model, Prdx4 knockdown limited GBM infiltration and significantly prolonged mouse survival. These data suggest that PRDX4 can be a novel target for GBM therapies in the future...
  22. doi BMPing off glioma stem cells
    Ichiro Nakano
    Department of Neurological Surgery, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    Cancer Cell 13:3-4. 2008
    ..These findings document the importance of the BMP signaling system in BTSC as well as that of taking heterogeneity into account when studying BTSC as potential targets for therapy...
  23. doi Transcription factors as master regulator for cancer stemness: remove milk from fox?
    Ichiro Nakano
    Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University, 385 Wiseman Hall, OSUCCC, Columbus, OH 43210, USA
    Expert Rev Anticancer Ther 14:873-5. 2014
    ..This editorial describes FOXM1 signaling in cancers and its potential therapeutic development. ..
  24. pmc Ethics of iPSC-based clinical research for age-related macular degeneration: patient-centered risk-benefit analysis
    Mariko Nakano-Okuno
    Department of Internal Medicine, The Ohio State University College of Medicine, B054 Graves Hall, 333 W 10th Ave, Columbus, OH, 43210, USA
    Stem Cell Rev 10:743-52. 2014
    ..The arguments presented will assist patients in undertaking a more informed decision-making process. ..
  25. ncbi [Cancer stem cells in malignant glioma-the mechanism of cancer initiation and the therapeutic development]
    Ichiro Nakano
    Department of Neurological Surgery, The Ohio State University, Ohio, USA Ichiro Nakano osumc edu
    No Shinkei Geka 38:879-89. 2010
    ..In this study, we summarize the recent findings and approaches in the cancer stem cell field, mainly focusing on malignant glioma stem cells, and also describe potential future directions in this area...